IBDEI0DB ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17787,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,17788,0)
 ;;=202.00^^110^990^88
 ;;^UTILITY(U,$J,358.3,17788,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17788,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,17788,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,17788,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,17789,0)
 ;;=200.10^^110^990^87
 ;;^UTILITY(U,$J,358.3,17789,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17789,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,17789,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,17789,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,17790,0)
 ;;=273.3^^110^990^90
 ;;^UTILITY(U,$J,358.3,17790,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17790,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,17790,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,17790,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,17791,0)
 ;;=203.00^^110^990^99
 ;;^UTILITY(U,$J,358.3,17791,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17791,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,17791,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,17791,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,17792,0)
 ;;=203.01^^110^990^98
 ;;^UTILITY(U,$J,358.3,17792,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17792,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,17792,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,17792,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,17793,0)
 ;;=238.6^^110^990^102
 ;;^UTILITY(U,$J,358.3,17793,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17793,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,17793,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,17793,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,17794,0)
 ;;=205.00^^110^990^5
 ;;^UTILITY(U,$J,358.3,17794,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17794,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,17794,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,17794,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,17795,0)
 ;;=205.01^^110^990^4
 ;;^UTILITY(U,$J,358.3,17795,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17795,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,17795,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,17795,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,17796,0)
 ;;=205.10^^110^990^29
 ;;^UTILITY(U,$J,358.3,17796,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17796,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,17796,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,17796,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,17797,0)
 ;;=205.11^^110^990^28
 ;;^UTILITY(U,$J,358.3,17797,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17797,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,17797,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,17797,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,17798,0)
 ;;=289.0^^110^990^52
 ;;^UTILITY(U,$J,358.3,17798,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17798,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,17798,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,17798,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,17799,0)
 ;;=238.4^^110^990^103
 ;;^UTILITY(U,$J,358.3,17799,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17799,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,17799,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,17799,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,17800,0)
 ;;=V58.61^^110^990^124
 ;;^UTILITY(U,$J,358.3,17800,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17800,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,17800,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,17800,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,17801,0)
 ;;=282.49^^110^990^116
 ;;^UTILITY(U,$J,358.3,17801,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17801,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,17801,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,17801,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,17802,0)
 ;;=289.89^^110^990^18
 ;;^UTILITY(U,$J,358.3,17802,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17802,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,17802,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,17802,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,17803,0)
 ;;=238.79^^110^990^85
 ;;^UTILITY(U,$J,358.3,17803,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17803,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,17803,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,17803,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,17804,0)
 ;;=287.30^^110^990^104
 ;;^UTILITY(U,$J,358.3,17804,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17804,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,17804,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,17804,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,17805,0)
 ;;=288.09^^110^990^8
 ;;^UTILITY(U,$J,358.3,17805,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17805,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,17805,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,17805,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,17806,0)
 ;;=284.81^^110^990^15
 ;;^UTILITY(U,$J,358.3,17806,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17806,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,17806,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,17806,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,17807,0)
 ;;=284.89^^110^990^14
 ;;^UTILITY(U,$J,358.3,17807,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17807,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,17807,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,17807,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,17808,0)
 ;;=284.9^^110^990^12
 ;;^UTILITY(U,$J,358.3,17808,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17808,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,17808,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,17808,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,17809,0)
 ;;=289.84^^110^990^117
 ;;^UTILITY(U,$J,358.3,17809,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17809,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,17809,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,17809,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,17810,0)
 ;;=204.02^^110^990^3
 ;;^UTILITY(U,$J,358.3,17810,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17810,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,17810,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,17810,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,17811,0)
 ;;=204.12^^110^990^25
 ;;^UTILITY(U,$J,358.3,17811,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17811,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,17811,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,17811,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,17812,0)
 ;;=204.21^^110^990^112
 ;;^UTILITY(U,$J,358.3,17812,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17812,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,17812,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,17812,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,17813,0)
 ;;=204.20^^110^990^113
 ;;^UTILITY(U,$J,358.3,17813,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17813,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,17813,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,17813,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,17814,0)
 ;;=204.22^^110^990^114
 ;;^UTILITY(U,$J,358.3,17814,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17814,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,17814,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,17814,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,17815,0)
 ;;=203.02^^110^990^100
 ;;^UTILITY(U,$J,358.3,17815,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17815,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,17815,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,17815,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,17816,0)
 ;;=205.02^^110^990^6
 ;;^UTILITY(U,$J,358.3,17816,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17816,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,17816,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,17816,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,17817,0)
 ;;=205.12^^110^990^27
 ;;^UTILITY(U,$J,358.3,17817,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17817,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,17817,1,5,0)
 ;;=5^CML in Relapse
 ;;^UTILITY(U,$J,358.3,17817,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,17818,0)
 ;;=V10.91^^110^990^63
 ;;^UTILITY(U,$J,358.3,17818,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17818,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,17818,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,17818,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,17819,0)
 ;;=V10.91^^110^990^72
 ;;^UTILITY(U,$J,358.3,17819,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17819,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,17819,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,17819,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,17820,0)
 ;;=465.9^^110^991^73
 ;;^UTILITY(U,$J,358.3,17820,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17820,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,17820,1,5,0)
 ;;=5^Uri
 ;;^UTILITY(U,$J,358.3,17820,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,17821,0)
 ;;=462.^^110^991^60
 ;;^UTILITY(U,$J,358.3,17821,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17821,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,17821,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,17821,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,17822,0)
 ;;=466.0^^110^991^3
 ;;^UTILITY(U,$J,358.3,17822,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17822,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,17822,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,17822,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,17823,0)
 ;;=112.1^^110^991^78
 ;;^UTILITY(U,$J,358.3,17823,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17823,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,17823,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,17823,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,17824,0)
 ;;=616.0^^110^991^13
 ;;^UTILITY(U,$J,358.3,17824,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,17824,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,17824,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,17824,2)
 ;;=^21925
